Patent intelligence · US
US 12304908
Azabenzimidazoles and their use as AMPA receptor modulators
Azabenzimidazoles and their use as AMPA receptor modulators
Patent details — US 12304908
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 20, 2025
- Expiration
- May 15, 2045
- Applicant
- Rapport Therapeutics, Inc.
- Claims
- 2
- CPC classes
- A61P, A61P25/00
Quick answer
US 12304908 (Azabenzimidazoles and their use as AMPA receptor modulators) is held by Rapport Therapeutics, Inc.. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rapport Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P25/00
Frequently asked questions
What is US patent 12304908?
US 12304908 (Azabenzimidazoles and their use as AMPA receptor modulators) is held by Rapport Therapeutics, Inc.. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12304908?
Rapport Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12304908 expire?
Our index shows an expiration date of May 15, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.